FDA counterfeit bulk drug information requested by House Commerce Committee.
This article was originally published in The Tan Sheet
Executive Summary
FDA COUNTERFEIT BULK DRUG INFO REQUESTED BY HOUSE COMMERCE CMTE. Chairman Thomas Bliley (R-Va.) and Oversight Subcommittee Chairman Joe Barton (R-Tex.) in the form of complete records of agency meetings and actions on the subject in anticipation of hearings on the agency's foreign inspection program. An Aug. 4 letter requests a list of "all FDA enforcement actions and/or investigations" involving counterfeit bulk drug substances since Jan. 1, 1990. The committee also wants copies of all internal FDA records relating to counterfeit bulk drugs during the same period.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning